Skip to main content

Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493).

Publication ,  Journal Article
Frankel, LS; Ochs, J; Shuster, JJ; Dubowy, R; Bowman, WP; Hockenberry Eaton, M; Borowitz, M; Carroll, AJ; Steuber, CP; Pullen, DJ
Published in: Journal of pediatric hematology/oncology
April 1997

OBJECTIVE: Despite improved event-free survival of older children with acute lymphocytic leukemia (ALL), infants 50,000/microl), and a higher likelihood of CD-10 (CALLA) negative lymphoblasts (55%). A translocation involving chromosome 11 at band q23 was detected in 27 of 64 cytogenetically informative cases. Treatment was based upon two institutional pilot studies utilizing chemotherapy doses based upon body weight. Important components included remission induction with cyclophosphamide (Ctx), vincristine (Vcr), cytosine arabinoside (Ara-C), and prednisone (Pred) (COAP); consolidation therapy with teniposide (VM-26) and Ara-C; and continuation therapy with alternating pulses of COAP with VM-26/Ara-C separated by a methotrexate (Mtx) and 6-mercaptopurine (6-MP) backbone plus CNS therapy consisting of standard triple intrathecal therapy (TIT) (Mtx/hydrocortisone/Ara-C), which avoided the use of radiotherapy in this population. RESULTS: Seventy-six infants achieved a complete remission (93%). Fifty patients have relapsed: 35 isolated marrow relapses, five isolated CNS relapses, eight combined marrow and CNS relapses, and two other relapses. Actuarial event-free survival was 28% (SE = 5%) at 4 years. Infants >274 days (9 months) at diagnosis had a better outcome than those

Duke Scholars

Published In

Journal of pediatric hematology/oncology

ISSN

1077-4114

Publication Date

April 1997

Volume

19

Issue

1

Start / End Page

35 / 42

Related Subject Headings

  • Treatment Outcome
  • Recurrence
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Oncology & Carcinogenesis
  • Infant
  • Humans
  • Antineoplastic Combined Chemotherapy Protocols
  • Age Factors
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Frankel, L. S., Ochs, J., Shuster, J. J., Dubowy, R., Bowman, W. P., Hockenberry Eaton, M., … Pullen, D. J. (1997). Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). Journal of Pediatric Hematology/Oncology, 19(1), 35–42.
Frankel, L. S., J. Ochs, J. J. Shuster, R. Dubowy, W. P. Bowman, M. Hockenberry Eaton, M. Borowitz, A. J. Carroll, C. P. Steuber, and D. J. Pullen. “Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493).Journal of Pediatric Hematology/Oncology 19, no. 1 (April 1997): 35–42.
Frankel LS, Ochs J, Shuster JJ, Dubowy R, Bowman WP, Hockenberry Eaton M, et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). Journal of pediatric hematology/oncology. 1997 Apr;19(1):35–42.
Frankel, L. S., et al. “Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493).Journal of Pediatric Hematology/Oncology, vol. 19, no. 1, Apr. 1997, pp. 35–42.
Frankel LS, Ochs J, Shuster JJ, Dubowy R, Bowman WP, Hockenberry Eaton M, Borowitz M, Carroll AJ, Steuber CP, Pullen DJ. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). Journal of pediatric hematology/oncology. 1997 Apr;19(1):35–42.

Published In

Journal of pediatric hematology/oncology

ISSN

1077-4114

Publication Date

April 1997

Volume

19

Issue

1

Start / End Page

35 / 42

Related Subject Headings

  • Treatment Outcome
  • Recurrence
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Oncology & Carcinogenesis
  • Infant
  • Humans
  • Antineoplastic Combined Chemotherapy Protocols
  • Age Factors
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology